Medicus Pharma Ltd. (MDCX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$6.4M
Cash & Equivalents
$9.0M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$23M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT02629159 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S... | PHASE3 | Active Not Recruiting | 1,629 |
| NCT06846541 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | PHASE3 | Active Not Recruiting | 1,680 |
| NCT03398135 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | PHASE3 | Active Not Recruiting | 1,242 |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | PHASE3 | Recruiting | 5,056 |
| NCT07599813 | A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | PHASE2 | Recruiting | 280 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.